Iodide benzamides for the in-vivo detection of melanoma and metastases

Melanoma Research

Volumn 16, Issue 1, 2006, Pages 37-43

  Edreira, Martin M ^a,b   Pozzi, Oscar R ^a,c  

^a DEPARTAMENTO DE FÍSICA   (Argentina)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

131I MBA; B16; Benzamides; Melanoma; Metastases; Radiotracers

Indexed keywords

N (2 DIETHYLAMINOETHYL) 3 IODO 4 METHYLBENZAMIDE I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; IODOBENZENE; N (2 DIETHYLAMINOETHYL) 3 IODO 4 METHOXYBENZAMIDE; N-(2-DIETHYLAMINOETHYL)-3-IODO-4-METHOXYBENZAMIDE; RADIOACTIVE IODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; IODINATION; ISOTOPE LABELING; KIDNEY CLEARANCE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; RADIOACTIVITY; RADIOCHEMISTRY; SUBCUTANEOUS TISSUE TUMOR; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; EXPERIMENTAL MELANOMA; LUNG TUMOR; PATHOLOGY; SCINTISCANNING; SKIN TUMOR;

ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; IODINE RADIOISOTOPES; IODOBENZENES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RADIOPHARMACEUTICALS; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33645461346     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000195701.73192.7b     Document Type: Article

References (29)

1. Serraino D, Fratino L, Gienni W, Campisi C, Pietropaolo M, Trimarco G, et al. Epidemiological aspects of cutaneous malignant melanoma. Oncol Rep 1998; 5:905-909.
2. Whited JD, Grichnik JM. Does this patient have a mole or a melanoma? J Am Med Assoc 1998; 279:732-735.
3. Hall HI, Miller DR, Rogers JD, Bewers B. Update on the incidence and the mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40:35-42.
4. Hoefnagel CA. Role of nuclear medicine in melanoma. Eur J Nucl Med 1998; 25:1567-1574.
5. Ak I, Stokkel MPM, Bergman W, Pauwels EK. Cutaneous malignant melanoma: clinical aspects, imaging and treatment. Eur J Nucl Med 2000; 27:447-458.
6. 67Ga citrate. Eur J Nucl Med 1986; 12:96-104.
7. Coderre JA, Packer S, Fairchild RG, Greenberg D, Laster B, Micca P. Iodothiouracil as a melanoma localizing agent. J Nucl Med 1986; 27: 1157-1164.
8. Murphy RA, Kung HF, Kung M-P, Billings J. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents. J Med Chem 1990; 33:171-178.
9. Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med 1991; 32:1573-1580.
10. Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl-4-iodobenzamide). J Nucl Med 1993; 34:1260-1266.
11. Mohammed A, Nicholl C, Titsch U, Eisenhut M. Radioiodinated N-(alkylaminoalkyl)-substituted 4-methoxy-, 4-hydroxy-, and 4-aminobenzamides: biological investigations for the improvement of melanoma-imaging agents. Nucl Med Biol 1997; 24:373-380.
12. Moins N, Papona J, Seguinb H, Gardetteb D, Moreaua MF, Labarrea P, et al. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 2001; 28:799-808.
13. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med 2002; 29:1478-1484.
14. Maffioli L, Mascheroni L, Mongioj V, Gasparini M, Baldini MT, Seregni E, et al. Scintigraphic detection of melanoma metastases with a radiolabelled benzamide ([iodine-123]-(S)-IBZM). J Nucl Med 1994; 35:1741-1747.
15. Larisch R, Schulte K-W, Ruzicka T, Müller-Gärtner H-W. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. J Nucl Med 1998; 39:996-1001.
16. Eisenhut M, Hull WE, Mohammed A, Mier W, Lay D, Just W, et al. Radioiodinated N-(2-diethylaminoethyl) benzamide derivates with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem 2000; 43:3913-3922.
17. Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M. Pharmacokinetics of iodine-123-IMBA for melanoma imaging. J Nucl Med 1997; 38:127-133.
18. McKillop A, Fowler JS, Zelesko MJ, Hunt JD. Thallium in organic synthesis. X. A one-step synthesis of aryl iodides. Tetrahedron Lett 1969; 29: 2427-2430.
19. Institute of Laboratory Animal Resources, National Research Council. Guide for the care and use of laboratory animals. Washington DC: National Academy Press; 1996.
20. Guerquin-Kern JL, Hillion F, Madelmont JC, Labarre P, Papon J, Croisy A. Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed Eng Online 2004; 3:10.
21. Labarre P, Papon J, Moreau MF, Moins N, Bayle M, Veyre, et al. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanoma Res 2002; 12:115-121.
22. Boni R, Steinert H, Boni RA, Lichtensteiger W, Dummer R, Hartman DS, et al. Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzfurans with melanin. Dermatology 1996; 6193:198-202.
23. Brandau W, Neihoff T, Pulewski P, Jones M, Dutschka K, Sciuk J, et al. Structure-distribution relationship of iodine-123-iodobenzamides as tracers for the detection of melanotic melanoma. J Nucl Med 1996; 37:1865-1871.
24. Dittman H, Coenen HH, Zolzer F, Dutschka K, Brandau W, Streffer C. In vitro studies on the cellular uptake of melanoma imaging aminoalkyliodobenzamide derivates (ABA). Nucl Med Biol 1999; 26:51-56.
25. Mansard S, Papon J, Moreau MF, Miot-Noirault E, Labarre P, Bayle M, et al. Uptake in melanoma cells of N-(2-diethylaminoethyl)-2-iodobenzamide (BZA2), an imaging agent for melanoma staging: relation to pigmentation. Nucl Med Biol 2005; 32:451-458.
26. Wolf M, Bauder-Wust U, Haberkorn U, Mier W, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: role of melanin, tyrosinase, intracellular pH and DNA interaction. Melanoma Res 2005; 15: 383-391.
27. Moreau M, Papon J, Labarre P, Moins N, Borel M, Bayle M, et al. Synthesis, in vitro binding and biodistribution in B16 melanoma-bearing mice of new iodine-125 spermidine benzamide derivatives. Nucl Med Biol 2005; 32:377-384.
28. Bacin F, Michelot J, Bonafous J, Veyre A, Moreau MF, Kemeny JL, et al. Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma. Acta Ophthalmol Scand 1998; 76:56-61.
29. Sillaire-Houtmann I, Bonafous J, Veyre A, Mestas D, D'Incan M, Moins N, et al. Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma. J Fr Ophthalmol 2004; 27:34-39.